Market analysts expect the demand for these drugs to continue to grow significantly, with the global market size forecast to reach between $75bn to $140bn (2030+)
GLP-1 receptor agonists as a drug class have substantial clinical trial evidence supporting significant weight loss outcomes, with peer-reviewed research demonstrating statistically meaningful reductions in body weight in large randomized controlled trials
Just remember that coverage can vary based on your specific plan, so its important to understand what your plan covers before beginning any new treatment
ongoing support, monitoring, and concierge access
Rest, hydration, and balanced meals often reduce these symptoms
Reported side effects Mild headache or fatigue typically transient during initial use Mild gastrointestinal discomfort reported in some oral formulation users Sleep disruption or irritability potential sign of overstimulation Theoretical safety concerns Critical note: Because Dihexa activates the HGF/c-Met pathway which promotes cellular growth and repair there is a theoretical concern that it could potentially stimulate unwanted cell proliferation in individuals with active cancer or high cancer risk
